Overview
Dr. Schmader’s areas of research include herpes zoster, infections, and vaccines in older adults. He conducts translational, clinical trials and observational studies of zoster, influenza, and other infections funded by grants from the National Institute on Aging (NIA), National Institute of Allergy and Infectious Diseases (NIAID), Centers for Disease Control (CDC), VA Office of Research and Development, and Industry sources. He has played a pivotal role in the development of zoster vaccines in older adults. Dr. Schmader also performs research in medications and older adults, focusing on pharmacoepidemiology, optimal drug use and reduction of adverse drug reactions.
He is the Director of the NIA-funded P30 Duke Pepper Older Americans Independence Center, Co-investigator of the NIAID funded Collaborative Influenza Vaccine Innovation Centers (CIVICS) and the CDC Clinical Immunization Safety Assessment (CISA) office at Duke. He serves on the Working Groups for the Herpes Zoster, Influenza, COVID-19, RSV and General Adult Immunization Guidelines for the US Centers for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) and is the American Geriatrics Society liaison to the ACIP.
Current Appointments & Affiliations
Recent Publications
Adopting Principles to Guide Pathways: The Best Model for Geriatric Pain Management.
Journal Article Clin Geriatr Med · February 2026 Older adults experience the highest burden of chronic pain and pain-related disability. Existing pathways-multimodal, stepped, and stratified prove useful pieces but do not fully account for the complexity of geriatric care. This article argues for princip ... Full text Link to item CiteCan Pharmacogenetics Be Used to Predict the Response to Fesoterodine Fumarate?
Journal Article Urogynecology (Phila) · January 1, 2026 IMPORTANCE: Pharmacogenetics could address the challenge of predicting an individual's response to anticholinergic medications for urgency urinary incontinence (UUI). OBJECTIVES: Our objectives were to evaluate whether the metabolizer status of cytochrome ... Full text Link to item CiteImmunogenicity of mRNA COVID-19 vaccine with either simultaneous or sequentially administered inactivated influenza vaccines: a randomized clinical trial.
Journal Article Vaccine · December 10, 2025 BACKGROUND: A U.S. multisite trial was conducted and explored whether blunting of mRNA COVID-19 vaccine immunogenicity occurred when administered simultaneously with influenza vaccine. METHODS: Persons ≥5 years of age received either quadrivalent inactivat ... Full text Link to item CiteRecent Grants
Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations (INSPIRE-COPD-E).
ResearchMentor · Awarded by National Institutes of Health · 2025 - 2030Duke/UNC ADAR Program
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2024 - 2029CISA 2023 Clinical Contributing Task 1
ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2023 - 2028View All Grants